Skip to Main Content

Paper Details

Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials.
J Clin Oncol
34
2023
DRFI, ER, Exemestane, OFS, PgR, Premenopausal Breast Cancer, breast cancer, estrogen, exemestane, grade, grade 3 tumors, human epidermal, human epidermal growth, human epidermal growth factor receptor 2, patients, progesterone, progesterone receptor, tamoxifen, women
Author NameAffiliation
Matthew P GoetzMayo Clinic and Alliance for Clinical Trials in Oncology
Vered StearnsJohns Hopkins Sidney Kimmel Comprehensive Cancer Center and ECOG-ACRIN
Eric P WinerSusan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, Harvard Medical School and Alliance for Clinical Trials in Oncology
Eric P WinerYale Cancer Center, Yale School of Medicine Smilow Cancer Hospital
Meredith M ReganDana-Farber Cancer Institute, Harvard Medical School
  • 1 - 5

Datasets

Release 1.2